You-Jung Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
You-Jung Choi has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Jin Oh Na
Division of Cardiology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea
8 shared publications - Jun-Bean Park
Cardiovascular Center, Seoul National University Hospital, Seoul, Korea
8 shared publications - Hyun-Jung Lee
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
6 shared publications - Hyung-Kwan Kim
Seoul National University Hospital
6 shared publications - Jah Yeon Choi
Division of Cardiology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine , Seoul
6 shared publications - Jieun Lee
Division of Cardiology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea
6 shared publications
Latest Publications
- Open Access
- 23 June 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (25) , 2011-2028
Integrative Molecular Analyses of Inflammatory and Autoimmune Signals in Cardiac Sarcoidosis
BACKGROUND: Cardiac sarcoidosis (CS) is an enigmatic disorder characterized by unexplained patchy, sterile granulomas intermixed with preserved myocardium and fibrotic regions without granuloma. CS causes arrhythmias, sudden cardiac death, and heart failure. The mechanisms producing this remarkable histopathology and disease progression remain unexplained. METHODS: Using comprehensive single-cell and spatial transcriptomic analyses, we characterized the cellular composition and gene expression in preserved, granulomatous, and fibrotic regions of human CS hearts. From unexpectedly identified clonally expanded cardiac B cells with rearranged immunoglobulin sequences, we reconstructed antibodies and screened libraries comprising the human peptidome or microbial and allergen peptides to define reactive epitopes in CS hearts. RESULTS: Cellular composition and gene expression differed substantially in CS tissues with preserved, granulomatous, or fibrotic histopathology. Cardiomyocytes upregulated arrhythmogenic and inflammasome transcripts associated with pyroptosis. Cardiomyocytes and fibroblasts activated chemoattractant cytokines that sustained myeloid and lymphoid infiltration. Granulomas contained abundant macrophages expressing modulators of cell–cell fusion, along with Th17-skewed T cells that upregulated B-cell–activating factor, thereby promoting antibody production. Fibrotic regions, without active granulomas, exhibited tertiary lymphoid structures, with clonal expansion of mature B and plasma cells. Reconstructed antibodies derived from expanded B-cell clones were inert to microbial and allergen peptides, but reacted to PPL (periplakin), a desmosome protein, and other peptides expressed on cardiac cells. CONCLUSIONS: Progressive inflammatory signals in CS are mediated by chemoattractant genes in cardiomyocytes and fibroblasts within preserved myocardium, cell–cell fusion modulators in activated macrophages within granulomatous regions, and tertiary lymphoid structures in fibrotic regions that produce patient-specific autoimmune antibodies. Identification of PPL as a CS autoantigen may account for shared clinical manifestations in CS and arrhythmic desmosomal cardiomyopathies. CS autoantigens may underlie enigmatic histopathologic findings, perpetuate disease, and contribute to adverse outcomes. Uncovering an intracardiac humoral autoimmune axis in CS provides specific therapeutic opportunities to limit granuloma formation and B-cell activation, which may reduce arrhythmogenicity and progressive dysfunction. Parallel analytic strategies have potential to define autoantigens in other enigmatic cardiac immune disorders.
- 23 June 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (25) , 2011-2028
Open AccessIntegrative Molecular Analyses of Inflammatory and Autoimmune Signals in Cardiac Sarcoidosis
BACKGROUND: Cardiac sarcoidosis (CS) is an enigmatic disorder characterized by unexplained patchy, sterile granulomas intermixed with preserved myocardium and fibrotic regions without granuloma. CS causes arrhythmias, sudden cardiac death, and heart failure. The mechanisms producing this remarkable histopathology and disease progression remain unexplained. METHODS: Using comprehensive single-cell and spatial transcriptomic analyses, we characterized the cellular composition and gene expression in preserved, granulomatous, and fibrotic regions of human CS hearts. From unexpectedly identified clonally expanded cardiac B cells with rearranged immunoglobulin sequences, we reconstructed antibodies and screened libraries comprising the human peptidome or microbial and allergen peptides to define reactive epitopes in CS hearts. RESULTS: Cellular composition and gene expression differed substantially in CS tissues with preserved, granulomatous, or fibrotic histopathology. Cardiomyocytes upregulated arrhythmogenic and inflammasome transcripts associated with pyroptosis. Cardiomyocytes and fibroblasts activated chemoattractant cytokines that sustained myeloid and lymphoid infiltration. Granulomas contained abundant macrophages expressing modulators of cell–cell fusion, along with Th17-skewed T cells that upregulated B-cell–activating factor, thereby promoting antibody production. Fibrotic regions, without active granulomas, exhibited tertiary lymphoid structures, with clonal expansion of mature B and plasma cells. Reconstructed antibodies derived from expanded B-cell clones were inert to microbial and allergen peptides, but reacted to PPL (periplakin), a desmosome protein, and other peptides expressed on cardiac cells. CONCLUSIONS: Progressive inflammatory signals in CS are mediated by chemoattractant genes in cardiomyocytes and fibroblasts within preserved myocardium, cell–cell fusion modulators in activated macrophages within granulomatous regions, and tertiary lymphoid structures in fibrotic regions that produce patient-specific autoimmune antibodies. Identification of PPL as a CS autoantigen may account for shared clinical manifestations in CS and arrhythmic desmosomal cardiomyopathies. CS autoantigens may underlie enigmatic histopathologic findings, perpetuate disease, and contribute to adverse outcomes. Uncovering an intracardiac humoral autoimmune axis in CS provides specific therapeutic opportunities to limit granuloma formation and B-cell activation, which may reduce arrhythmogenicity and progressive dysfunction. Parallel analytic strategies have potential to define autoantigens in other enigmatic cardiac immune disorders.
- 5 May 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Cardiovascular risk in women with metabolic dysfunction-associated steatotic liver disease across the menopausal transition
Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) poses a substantial global health burden, yet the cardiovascular impact across menopausal status remains unclear. Thus, this study aimed to assess the association between MASLD and cardiovascular risk in premenopausal and postmenopausal women. Methods and results: We conducted a nationwide population-based cohort study using the Korean National Health Insurance Service database. Women aged 40 years or older were categorized by the fatty liver index as having no MASLD (<30), grade 1 (30–59), or grade 2 (≥60). The primary outcome was major adverse cardiovascular events (MACE), defined as a composite of myocardial infarction, ischaemic stroke, and cardiovascular death. Among 1 931 330 women aged 40 years or older, including 837 363 premenopausal and 1 093 967 postmenopausal women, MACE incidence (per 1000 person-years) increased with MASLD severity: 1.82, 2.93, and 3.91 in premenopausal women, and 7.68, 10.55, and 12.36 in postmenopausal women. 5-year absolute MACE risks also rose with MASLD severity: premenopausal (0.45% [95% CI 0.44–0.47%], 0.65% [95% CI 0.62–0.68%], 0.87% [95% CI 0.82–0.93%]) and postmenopausal (2.74% [95% CI 2.71–2.77%], 3.25% [95% CI 3.20–3.30%], 3.83% [95% CI 3.75–3.91%]). Absolute risk differences between no MASLD and grades 1 or 2 were over twice as large in postmenopausal women (0.51% [95% CI 0.47–0.55%] and 1.09% [95% CI 1.02–1.17%]) than in premenopausal women (0.20% [95% CI 0.17–0.22%] and 0.42% [95% CI 0.37–0.47%]). Conclusion: MASLD was associated with increased cardiovascular risk in both premenopausal and postmenopausal women. The absolute excess risk associated with MASLD was larger in postmenopausal women. These findings emphasize incorporating hepatic steatosis severity and menopausal status into cardiovascular risk assessment and prevention strategies for women’s health.
- 5 May 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Cardiovascular risk in women with metabolic dysfunction-associated steatotic liver disease across the menopausal transition
Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) poses a substantial global health burden, yet the cardiovascular impact across menopausal status remains unclear. Thus, this study aimed to assess the association between MASLD and cardiovascular risk in premenopausal and postmenopausal women. Methods and results: We conducted a nationwide population-based cohort study using the Korean National Health Insurance Service database. Women aged 40 years or older were categorized by the fatty liver index as having no MASLD (<30), grade 1 (30–59), or grade 2 (≥60). The primary outcome was major adverse cardiovascular events (MACE), defined as a composite of myocardial infarction, ischaemic stroke, and cardiovascular death. Among 1 931 330 women aged 40 years or older, including 837 363 premenopausal and 1 093 967 postmenopausal women, MACE incidence (per 1000 person-years) increased with MASLD severity: 1.82, 2.93, and 3.91 in premenopausal women, and 7.68, 10.55, and 12.36 in postmenopausal women. 5-year absolute MACE risks also rose with MASLD severity: premenopausal (0.45% [95% CI 0.44–0.47%], 0.65% [95% CI 0.62–0.68%], 0.87% [95% CI 0.82–0.93%]) and postmenopausal (2.74% [95% CI 2.71–2.77%], 3.25% [95% CI 3.20–3.30%], 3.83% [95% CI 3.75–3.91%]). Absolute risk differences between no MASLD and grades 1 or 2 were over twice as large in postmenopausal women (0.51% [95% CI 0.47–0.55%] and 1.09% [95% CI 1.02–1.17%]) than in premenopausal women (0.20% [95% CI 0.17–0.22%] and 0.42% [95% CI 0.37–0.47%]). Conclusion: MASLD was associated with increased cardiovascular risk in both premenopausal and postmenopausal women. The absolute excess risk associated with MASLD was larger in postmenopausal women. These findings emphasize incorporating hepatic steatosis severity and menopausal status into cardiovascular risk assessment and prevention strategies for women’s health.
- Open Access
- 25 August 2025
- Published by Springer Nature in Journal of Cardiovascular Imaging
- Vol. 33 (1) , 1-12
Atrial fibrillation and thromboembolic risk in hypertrophic cardiomyopathy
Atrial fibrillation (AF) is the most common sustained arrhythmia in patients with hypertrophic cardiomyopathy (HCM), conferring a markedly increased risk of thromboembolic events. Conventional risk stratification tools such as the CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75 years [doubled], diabetes mellitus, prior stroke or transient ischemic attack [doubled], vascular disease, age 65–74 years, female sex) score are often insufficient to predict thromboembolic events in patients with HCM and AF, as thromboembolic risk in HCM is driven by disease-specific structural, functional, and prothrombotic substrates. This review synthesizes current evidence on the epidemiology, pathophysiological mechanisms, and clinical impact of AF and thromboembolism in HCM. We discuss variable imaging modalities—including strain echocardiography, cardiac magnetic resonance, and cardiac computed tomography—that offer enhanced characterization of atrial remodeling and thromboembolic risk in patients with HCM. Furthermore, we outline current guideline-based anticoagulation strategies, the evolving role of direct oral anticoagulants, and adjunctive therapies such as left atrial appendage occlusion and catheter ablation. A comprehensive, multidisciplinary approach that incorporates advanced imaging, molecular profiling, and individualized management is ideal to optimize outcomes and reduce stroke burden in patients with HCM and AF.
- 25 August 2025
- Published by Springer Nature in Journal of Cardiovascular Imaging
- Vol. 33 (1) , 1-12
Open AccessAtrial fibrillation and thromboembolic risk in hypertrophic cardiomyopathy
Atrial fibrillation (AF) is the most common sustained arrhythmia in patients with hypertrophic cardiomyopathy (HCM), conferring a markedly increased risk of thromboembolic events. Conventional risk stratification tools such as the CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75 years [doubled], diabetes mellitus, prior stroke or transient ischemic attack [doubled], vascular disease, age 65–74 years, female sex) score are often insufficient to predict thromboembolic events in patients with HCM and AF, as thromboembolic risk in HCM is driven by disease-specific structural, functional, and prothrombotic substrates. This review synthesizes current evidence on the epidemiology, pathophysiological mechanisms, and clinical impact of AF and thromboembolism in HCM. We discuss variable imaging modalities—including strain echocardiography, cardiac magnetic resonance, and cardiac computed tomography—that offer enhanced characterization of atrial remodeling and thromboembolic risk in patients with HCM. Furthermore, we outline current guideline-based anticoagulation strategies, the evolving role of direct oral anticoagulants, and adjunctive therapies such as left atrial appendage occlusion and catheter ablation. A comprehensive, multidisciplinary approach that incorporates advanced imaging, molecular profiling, and individualized management is ideal to optimize outcomes and reduce stroke burden in patients with HCM and AF.
- Open Access
- 1 January 2025
- Published by Human Kinetics in Journal of Aging and Physical Activity
- Vol. -1 (aop) , 1-11
Association of Handgrip Strength With Readmission, Mortality, and Exercise Capacity in Patients With Heart Failure
Background: Patients with heart failure (HF) experience a marked reduction in overall skeletal muscle strength and exercise capacity, which is detrimental to their prognosis. This study examined the clinical implications of handgrip strength (HGS) in patients with HF. Methods: Overall, 173 patients (mean age, 62 years; 81.5% male) underwent cardiac rehabilitation from 2015 to 2020. Baseline HGS was measured as the average value (kg) for both hands using a handheld dynamometer. For each patient, distance walked during a 6-min walk test and metabolic equivalents were recorded. The primary outcome was the composite of readmissions for HF and all-cause death. Results: Receiver operating characteristic curve for the primary outcome revealed 24.9 kg as the HGS cutoff point (area under curve: 0.702, 95% confidence interval [0.610, 0.794], p < .001) and multivariable Cox proportional hazard analysis revealed that lower HGS was significantly associated with a higher risk of readmission for HF or all-cause death (hazard ratio [HR] 6.44, 95% confidence interval [2.86, 14.50], p < .001). This result is mainly attributed to the increased risk of readmission for HF in this group (hazard ratio 6.75, 95% confidence interval [2.87, 15.88], p < .001). Moreover, HGS was significantly positively correlated with distance on 6-min walk test (r = .564, p < .001) and metabolic equivalents (r = .419, p < .001), and is one of the strongest predictors of each exercise capacity category. Conclusions: As our findings suggested, HGS is an indicator of exercise capacity and a useful marker for predicting hospital readmission or all-cause death in patients with HF.
- 1 January 2025
- Published by Human Kinetics in Journal of Aging and Physical Activity
- Vol. -1 (aop) , 1-11
Open AccessAssociation of Handgrip Strength With Readmission, Mortality, and Exercise Capacity in Patients With Heart Failure
Background: Patients with heart failure (HF) experience a marked reduction in overall skeletal muscle strength and exercise capacity, which is detrimental to their prognosis. This study examined the clinical implications of handgrip strength (HGS) in patients with HF. Methods: Overall, 173 patients (mean age, 62 years; 81.5% male) underwent cardiac rehabilitation from 2015 to 2020. Baseline HGS was measured as the average value (kg) for both hands using a handheld dynamometer. For each patient, distance walked during a 6-min walk test and metabolic equivalents were recorded. The primary outcome was the composite of readmissions for HF and all-cause death. Results: Receiver operating characteristic curve for the primary outcome revealed 24.9 kg as the HGS cutoff point (area under curve: 0.702, 95% confidence interval [0.610, 0.794], p < .001) and multivariable Cox proportional hazard analysis revealed that lower HGS was significantly associated with a higher risk of readmission for HF or all-cause death (hazard ratio [HR] 6.44, 95% confidence interval [2.86, 14.50], p < .001). This result is mainly attributed to the increased risk of readmission for HF in this group (hazard ratio 6.75, 95% confidence interval [2.87, 15.88], p < .001). Moreover, HGS was significantly positively correlated with distance on 6-min walk test (r = .564, p < .001) and metabolic equivalents (r = .419, p < .001), and is one of the strongest predictors of each exercise capacity category. Conclusions: As our findings suggested, HGS is an indicator of exercise capacity and a useful marker for predicting hospital readmission or all-cause death in patients with HF.
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (5) , e21
Evaluation of Burnout and Contributing Factors in Imaging Cardiologists in Korea
Choi YJ, et al. J Korean Med Sci. 2024 Nov;40:e21. https://doi.org/10.3346/jkms.2025.40.e21
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (5) , e21
Open AccessEvaluation of Burnout and Contributing Factors in Imaging Cardiologists in Korea
Choi YJ, et al. J Korean Med Sci. 2024 Nov;40:e21. https://doi.org/10.3346/jkms.2025.40.e21
- Open Access
- 1 January 2025
- Published by XMLink in Korean Circulation Journal
- Vol. 55 (2) , 161-163
Early Versus Late Initiation of Warfarin Post-Cesarean Section: A Step Forward in Managing Mechanical Heart Valve Patients
Choi YJ. Korean Circ J. 2024 Jul;54:e97. https://doi.org/10.4070/kcj.2024.0228
- 1 January 2025
- Published by XMLink in Korean Circulation Journal
- Vol. 55 (2) , 161-163
Open AccessEarly Versus Late Initiation of Warfarin Post-Cesarean Section: A Step Forward in Managing Mechanical Heart Valve Patients
Choi YJ. Korean Circ J. 2024 Jul;54:e97. https://doi.org/10.4070/kcj.2024.0228
- 1 October 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 17 (10) , e016302
Prognostic Value of Pulmonary Artery Systolic Pressure in Severe Rheumatic Mitral Stenosis
BACKGROUND: Current guidelines recommend intervention for asymptomatic rheumatic mitral stenosis (MS) with mitral valve area ≤1.5 cm 2 based on indicators including pulmonary arterial systolic pressure (PASP) >50 mm Hg and new-onset atrial fibrillation; however, evidence supporting this is lacking. METHODS: This single-center retrospective study included patients with rheumatic MS between 2006 and 2022. Pulmonary hypertension was evaluated by using echocardiography to estimate PASP. Primary outcomes were major adverse cardiovascular events (MACE), including all-cause mortality, hospitalization for heart failure, and arterial thromboembolic events for up to 5 years. RESULTS: Overall, 287 patients with severe rheumatic MS were enrolled (mean age, 62.5±11.3 years; 74.6% women). During a median follow-up of 2.52 years, MACE occurred in 99 patients. There were no differences in echocardiographic parameters, such as the mean mitral valve pressure gradient, mitral valve area, and proportion of mitral valve area 50 mm Hg than in those with ePASP ≤50 mm Hg (log-rank P P 45 mm Hg, which was an independent predictor of MACE in patients with severe rheumatic MS (adjusted hazard ratio, 2.127 [95% CI, 1.424–3.177]; P 45 mm Hg) as a predictor of an unfavorable prognosis.
- 1 October 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 17 (10) , e016302
Prognostic Value of Pulmonary Artery Systolic Pressure in Severe Rheumatic Mitral Stenosis
BACKGROUND: Current guidelines recommend intervention for asymptomatic rheumatic mitral stenosis (MS) with mitral valve area ≤1.5 cm 2 based on indicators including pulmonary arterial systolic pressure (PASP) >50 mm Hg and new-onset atrial fibrillation; however, evidence supporting this is lacking. METHODS: This single-center retrospective study included patients with rheumatic MS between 2006 and 2022. Pulmonary hypertension was evaluated by using echocardiography to estimate PASP. Primary outcomes were major adverse cardiovascular events (MACE), including all-cause mortality, hospitalization for heart failure, and arterial thromboembolic events for up to 5 years. RESULTS: Overall, 287 patients with severe rheumatic MS were enrolled (mean age, 62.5±11.3 years; 74.6% women). During a median follow-up of 2.52 years, MACE occurred in 99 patients. There were no differences in echocardiographic parameters, such as the mean mitral valve pressure gradient, mitral valve area, and proportion of mitral valve area 50 mm Hg than in those with ePASP ≤50 mm Hg (log-rank P P 45 mm Hg, which was an independent predictor of MACE in patients with severe rheumatic MS (adjusted hazard ratio, 2.127 [95% CI, 1.424–3.177]; P 45 mm Hg) as a predictor of an unfavorable prognosis.
- Open Access
- 15 September 2024
- Published by Korean Society of Epidemiology in Epidemiology and Health
- Vol. 46, e2024078
Temporal trends in the prevalence, incidence, and mortality of cardiac amyloidosis in Korea over 12 years
OBJECTIVES: This study investigated the prevalence, incidence, and prognosis of cardiac amyloidosis (CA) in Korea.METHODS: This retrospective nationwide population-based study used the Health Insurance Review and Assessment Service databases between 2008 and 2020. All patients diagnosed with amyloidosis were included, and those with a diagnosis of heart failure or cardiomyopathy were classified as having CA. Both the special code for amyloidosis (V121), which enables coverage of medical expenses, and the corresponding International Classification of Diseases, 10th revision codes for amyloidosis (E850- E854, E858, E859) were used to improve the reliability of amyloidosis diagnosis.RESULTS: Among 2,239 patients with amyloidosis, 758 met the criteria for CA (mean age, 64.4±11.9 years; 59.1% male). The mean age of patients with CA increased from 59.5±14.7 years in 2009 to 68.1±13.9 years in 2020. The incidence and prevalence increased from 0.09 (95% confidence interval [CI], 0.06 to 0.12) to 0.22 (95% CI, 0.18 to 0.27) per 100,000 person-years and 0.20 (95% CI, 0.16 to 0.25) to 1.30 (95% CI, 0.12 to 0.42) per 100,000 persons, respectively (all p<0.001). Patients with light-chain CA showed similar trends. In-hospital mortality decreased from 17.3% (95% CI, 9.23 to 29.6) to 6.10% (95% CI, 4.21 to 8.48) between 2009 and 2020. While age-specific in-hospital mortality was significantly higher in patients aged ≥70 years (p=0.004), no significant age-specific difference in in-hospital mortality was observed in patients with CA aged <70 years (p=0.981).CONCLUSIONS: The prevalence and incidence of CA have increased in Korea, predominantly affecting older individuals, particularly males. Notably, in-hospital mortality decreased significantly.
- 15 September 2024
- Published by Korean Society of Epidemiology in Epidemiology and Health
- Vol. 46, e2024078
Open AccessTemporal trends in the prevalence, incidence, and mortality of cardiac amyloidosis in Korea over 12 years
OBJECTIVES: This study investigated the prevalence, incidence, and prognosis of cardiac amyloidosis (CA) in Korea.METHODS: This retrospective nationwide population-based study used the Health Insurance Review and Assessment Service databases between 2008 and 2020. All patients diagnosed with amyloidosis were included, and those with a diagnosis of heart failure or cardiomyopathy were classified as having CA. Both the special code for amyloidosis (V121), which enables coverage of medical expenses, and the corresponding International Classification of Diseases, 10th revision codes for amyloidosis (E850- E854, E858, E859) were used to improve the reliability of amyloidosis diagnosis.RESULTS: Among 2,239 patients with amyloidosis, 758 met the criteria for CA (mean age, 64.4±11.9 years; 59.1% male). The mean age of patients with CA increased from 59.5±14.7 years in 2009 to 68.1±13.9 years in 2020. The incidence and prevalence increased from 0.09 (95% confidence interval [CI], 0.06 to 0.12) to 0.22 (95% CI, 0.18 to 0.27) per 100,000 person-years and 0.20 (95% CI, 0.16 to 0.25) to 1.30 (95% CI, 0.12 to 0.42) per 100,000 persons, respectively (all p<0.001). Patients with light-chain CA showed similar trends. In-hospital mortality decreased from 17.3% (95% CI, 9.23 to 29.6) to 6.10% (95% CI, 4.21 to 8.48) between 2009 and 2020. While age-specific in-hospital mortality was significantly higher in patients aged ≥70 years (p=0.004), no significant age-specific difference in in-hospital mortality was observed in patients with CA aged <70 years (p=0.981).CONCLUSIONS: The prevalence and incidence of CA have increased in Korea, predominantly affecting older individuals, particularly males. Notably, in-hospital mortality decreased significantly.
- 12 July 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (32) , 2983-2991
Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: a self-controlled case series study
Background and Aims: Concerns about the safety of coronavirus disease 2019 (COVID-19) vaccines in patients with atrial fibrillation/flutter (AF/AFL) have arisen due to reports of thrombo-embolic events following COVID-19 vaccination in the general population. This study aimed to evaluate the risk of thrombo-embolic events after COVID-19 vaccination in patients with AF/AFL. Methods: This was a modified self-controlled case-series study using a comprehensive nationwide-linked database provided by the National Health Insurance Service in South Korea to calculate incidence rate ratios (IRRs) of thrombo-embolic events. The study population included individuals aged ≥12 years who were either vaccinated (e.g. one or two doses) or unvaccinated during the period from February to December 2021. The primary outcome was a composite of thrombo-embolic events, including ischaemic stroke, transient ischaemic attack, and systemic thromboembolism. The risk period was defined as 0–21 days following COVID-19 vaccination. Results: The final analysis included 124 127 individuals with AF/AFL. The IRR of thrombo-embolic events within 21 days after COVID-19 vaccination, compared with that during the unexposed control period, was 0.93 [95% confidence interval (CI) 0.77–1.12]. No significant risk variations were noted by sex, age, or vaccine type. However, patients without anticoagulant therapy had an IRR of 1.88 (95% CI 1.39–2.54) following vaccination. Conclusions: In patients with AF/AFL, COVID-19 vaccination was generally not associated with an increased risk of thrombo-embolic events. However, careful individual risk assessment is required when advising vaccination for those not on oral anticoagulant, as these patients exhibited an increased risk of thrombo-embolic events post-vaccination.
- 12 July 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (32) , 2983-2991
Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: a self-controlled case series study
Background and Aims: Concerns about the safety of coronavirus disease 2019 (COVID-19) vaccines in patients with atrial fibrillation/flutter (AF/AFL) have arisen due to reports of thrombo-embolic events following COVID-19 vaccination in the general population. This study aimed to evaluate the risk of thrombo-embolic events after COVID-19 vaccination in patients with AF/AFL. Methods: This was a modified self-controlled case-series study using a comprehensive nationwide-linked database provided by the National Health Insurance Service in South Korea to calculate incidence rate ratios (IRRs) of thrombo-embolic events. The study population included individuals aged ≥12 years who were either vaccinated (e.g. one or two doses) or unvaccinated during the period from February to December 2021. The primary outcome was a composite of thrombo-embolic events, including ischaemic stroke, transient ischaemic attack, and systemic thromboembolism. The risk period was defined as 0–21 days following COVID-19 vaccination. Results: The final analysis included 124 127 individuals with AF/AFL. The IRR of thrombo-embolic events within 21 days after COVID-19 vaccination, compared with that during the unexposed control period, was 0.93 [95% confidence interval (CI) 0.77–1.12]. No significant risk variations were noted by sex, age, or vaccine type. However, patients without anticoagulant therapy had an IRR of 1.88 (95% CI 1.39–2.54) following vaccination. Conclusions: In patients with AF/AFL, COVID-19 vaccination was generally not associated with an increased risk of thrombo-embolic events. However, careful individual risk assessment is required when advising vaccination for those not on oral anticoagulant, as these patients exhibited an increased risk of thrombo-embolic events post-vaccination.
- Open Access
- 6 February 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (3) , e030552
Differing Efficacy of Dapagliflozin Versus Empagliflozin on the Risk of Incident Atrial Fibrillation in Patients With Type 2 Diabetes: A Real‐World Observation Using a Nationwide, Population‐Based Cohort
Background: Meta‐analyses of large clinical trials investigating SGLT2 (sodium‐glucose cotransporter‐2) inhibitors have suggested their protective effects against atrial fibrillation in patients with type 2 diabetes. However, the results were predominantly driven from trials involving dapagliflozin. Methods and Results: We used a nationwide, population‐based cohort of patients with type 2 diabetes who initiated either dapagliflozin or empagliflozin between May 2016 and December 2018. An active‐comparator, new‐user design was used, and the 2 groups of patients were matched using propensity scores. The primary outcome was incident nonvalvular atrial fibrillation, which was analyzed using both the main intention‐to‐treat and sensitivity analysis that censored patients who skipped their medications for ≥30 days. Men ≥55 years of age and women ≥60 years of age with ≥1 traditional risk factor or those with established cardiovascular disease were categorized as high cardiovascular risk group. Patients not included in the high‐risk group were categorized as low risk. After 1:1 propensity‐score matching, a total of 137 928 patients (mean age, 55 years; 58% men) were included and followed up for 2.2±0.6 years. The risk of incident atrial fibrillation was significantly lower in the dapagliflozin group in both the main (hazard ratio [HR], 0.885 [95% CI, 0.789–0.992]) and sensitivity analyses (HR, 0.835 [95% CI, 0.719–0.970]). Notably, this was consistent in both the low and high cardiovascular risk groups. There was no effect modification by age, sex, body mass index, duration of diabetes, or renal function. Conclusions: This real‐world, population‐based study demonstrates that patients with type 2 diabetes using dapagliflozin may have a lower risk of developing nonvalvular atrial fibrillation than those using empagliflozin.
- 6 February 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (3) , e030552
Open AccessDiffering Efficacy of Dapagliflozin Versus Empagliflozin on the Risk of Incident Atrial Fibrillation in Patients With Type 2 Diabetes: A Real‐World Observation Using a Nationwide, Population‐Based Cohort
Background: Meta‐analyses of large clinical trials investigating SGLT2 (sodium‐glucose cotransporter‐2) inhibitors have suggested their protective effects against atrial fibrillation in patients with type 2 diabetes. However, the results were predominantly driven from trials involving dapagliflozin. Methods and Results: We used a nationwide, population‐based cohort of patients with type 2 diabetes who initiated either dapagliflozin or empagliflozin between May 2016 and December 2018. An active‐comparator, new‐user design was used, and the 2 groups of patients were matched using propensity scores. The primary outcome was incident nonvalvular atrial fibrillation, which was analyzed using both the main intention‐to‐treat and sensitivity analysis that censored patients who skipped their medications for ≥30 days. Men ≥55 years of age and women ≥60 years of age with ≥1 traditional risk factor or those with established cardiovascular disease were categorized as high cardiovascular risk group. Patients not included in the high‐risk group were categorized as low risk. After 1:1 propensity‐score matching, a total of 137 928 patients (mean age, 55 years; 58% men) were included and followed up for 2.2±0.6 years. The risk of incident atrial fibrillation was significantly lower in the dapagliflozin group in both the main (hazard ratio [HR], 0.885 [95% CI, 0.789–0.992]) and sensitivity analyses (HR, 0.835 [95% CI, 0.719–0.970]). Notably, this was consistent in both the low and high cardiovascular risk groups. There was no effect modification by age, sex, body mass index, duration of diabetes, or renal function. Conclusions: This real‐world, population‐based study demonstrates that patients with type 2 diabetes using dapagliflozin may have a lower risk of developing nonvalvular atrial fibrillation than those using empagliflozin.